{"web_url": "http://www.nytimes.com/2016/01/06/business/sanofi-ends-marketing-deal-with-developer-of-inhaled-insulin.html", "snippet": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "multimedia": [{"height": 126, "subtype": "wide", "url": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "width": 190, "type": "image", "legacy": {"wideheight": "126", "wide": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "widewidth": "190"}}, {"height": 400, "subtype": "xlarge", "url": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg", "width": 600, "type": "image", "legacy": {"xlarge": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}}, {"height": 75, "subtype": "thumbnail", "url": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "width": 75, "type": "image", "legacy": {"thumbnail": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}}], "byline": {"original": "By ANDREW POLLACK", "person": [{"organization": "", "firstname": "Andrew", "lastname": "POLLACK", "rank": 1, "role": "reported"}]}, "lead_paragraph": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "abstract": "Insulin developer MannKind announces that Sanofi is ending agreement in which it had rights to market inhaled insulin called Afrezza; drug has not met sales expectations since Food and Drug Administration approval.", "keywords": [{"is_major": "Y", "rank": "1", "name": "organizations", "value": "Sanofi SA"}, {"is_major": "Y", "rank": "2", "name": "organizations", "value": "MannKind Corporation"}, {"is_major": "N", "rank": "3", "name": "persons", "value": "Mann, Alfred E"}, {"is_major": "N", "rank": "4", "name": "organizations", "value": "Pfizer Inc"}, {"is_major": "N", "rank": "5", "name": "organizations", "value": "Food and Drug Administration"}, {"is_major": "N", "rank": "6", "name": "subject", "value": "Diabetes"}], "section_name": "Business Day", "blog": [], "_id": "568c05fb38f0d803f4a0c464", "slideshow_credits": null, "pub_date": "2016-01-06T00:00:00Z", "type_of_material": "News", "print_page": "2", "subsection_name": null, "source": "The New York Times", "word_count": "914", "document_type": "article", "news_desk": "Business", "headline": {"print_headline": "Shares of Inhaled Insulin Maker Plummet 48% as Big Marketing Partner Pulls Out", "main": "Sanofi Ends Marketing Deal With Developer of Inhaled Insulin"}}